This research study aims to better understand patient experiences with accessing genetic counseling services for hypermobile Ehlers-Danlos syndrome (hEDS). The study will include a review of MUSC medical records to better understand referral patterns to genetic counseling services among patients with hEDS. Patients with hEDS will also be asked to complete a survey about their experiences with accessing genetic counseling services. Healthcare providers will be asked to complete a separate survey about their experiences referring patients with hEDS to genetic counseling services and potential factors that may influence the referral process. The surveys will take approximately 10-15 minutes to complete.

There are minimal risks to participants but may include possible loss of confidentiality or discomfort when answering questions related to healthcare experiences. There is no direct benefit to participants, but the information provided may help improve access to genetic counseling services for future patients with hEDS. Participation in the surveys is completely voluntary.

The FIORELLO study is for pediatric patients who 1) Have heart failure and left ventricular systolic dysfunction associated with dilated cardiomyopathy or congenital heart disease and 2) Have successfully completed the FIORE trial. Study participants will receive the study drug finerenone, which has not yet been FDA approved for this specific pediatric population. The study will last 9 months and the objective is to show that finerenone in addition to standard of care is safe when given long-term to pediatric patients with left ventricular systolic dysfunction.

This is a pilot study that will be performed to assess whether a series of once weekly in-home visits over a month (total of 4 visits) after discharge from a hospital with a heart failure diagnosis can help reduce re-hospitalization rates. To accomplish this, subjects will perform a once weekly telehealth visit with a heart failure provider and the following will be completed: symptom questionnaires, blood work, and a video of the neck veins to document physical exam once weekly during the study period. The videos and labs will be sent to the remote care team, who can use this data to manage the subject's medications. The study team will collect information regarding the study participant's frequency of hospital readmissions following enrollment.

This is a 3 month study for pediatric patients between the ages of 6 months and 18 years that have a current diagnosis of heart failure. This study will compare the use of the medication finerenone to placebo. During the study, participants will continue to receive their standard of care therapy according to pediatric heart failure guidelines. At the end of the 3 month study period, participants will have the option to enroll in a 9 month open label extension.

This study is enrolling patients with severe tricuspid regurgitation. Tricuspid regurgitation happens when your heart's tricuspid valve does not close tightly. The study will look at the safety and function of the investigational VDyne Transcatheter Tricuspid Replacement System (VDyne System). The VDyne System (Study Device) is experimental, which means it is not approved by the Food and Drug Administration (FDA), or any other relevant regulatory authority for commercial use. The VDyne System consists of an artificial heart valve and tools to place the valve into your heart. The VDyne Valve is designed to replace your tricuspid heart valve without open-heart surgery.

This study is randomized, meaning you will be assigned by chance to receive either the Study Device or the EVOQUE system, which is commercially approved by the FDA. The EVOQUE System is approved for use in the European Union (EU) (CE Mark) and the US (FDA).

Participation in this study will last about 5 years and include about 11 visits. Study related procedures included in these visits are physical exams, questionnaires, walking and moving from sitting to standing tests, blood tests, electrical measure of your heart's performance, ultrasound imaging of your heart, insertion of a thin tube to measure pressures through a blood vessel and monitor blood flow through your heart, and X-rays.

There are risks associated with the study such as: bleeding, injury to the system that controls your heartbeat, movement of the VDyne Valve from its implanted location, irritation of your esophagus, pain, inflammation, and skin/tissue injury. There are also risks related to study procedures such as other risks related with putting you to sleep for the procedure (general anesthesia) or other study related testing risks and the loss of confidentiality. Not all risks are known at known at this time. There may be benefit to you, although this cannot be guaranteed, but the information gained from you being in this study may benefit others with this condition in the future

The PRE-EMPT study is designed to identify people who may have early signs of heart disease even though they are considered to be at low risk for heart problems. Participants will undergo specialized heart scans to look for plaque buildup in the arteries that supply blood to the heart. Individuals found to have early plaque may be invited to participate in a treatment phase of the study. In this phase, participants will receive either study medications (rosuvastatin and/or colchicine) or placebo tablets and will also receive support for healthy lifestyle behaviors through a digital health platform. Patients will be randomized to one for four treatment groups. Researchers will follow participants for approximately two years to determine whether these treatments and lifestyle interventions can slow or reduce plaque buildup in the heart arteries. Information gained from this study may help improve strategies for detecting and treating early heart disease in the future.

Individuals with obesity and a history of heart failure (condition where heart does not effectively pump) with a preserved or mildly reduced ejection fraction (measure of the heart's pumping ability) will be eligible for participation. Study participants will have a 50:50 chance to be randomly assigned to either the treatment (NNC0487-0111) or control (placebo) group. NNC0487-011 and placebo will be delivered in an injectable pen device for a subcutaneous, once weekly injection. Placebo means there is no active study treatment) Study participation will last approximately three years and begin with a screening period to ensure correct patient selection. After the screening period, research clinic visits will occur every 4 weeks initially and then every 12 weeks. Some visits may be completed virtually through telehealth or by phone. Study procedures include but are not limited to: blood draws, questionnaires, self injection of study medication, medical history review, vital signs, and electrocardiogram (test that records the heart's electrical activity) The study's primary objective is to demonstrate that study drug vs. once weekly placebo, with standard of care, reduces the risk of a composite heart failure outcome consisting of cardiovascular death, heart failure hospitalization, or urgent heart failure visit in patients with heart failure with a preserved or mildly reduced ejection fraction and obesity.

This study is enrolling subjects with heart failure and a preserved fraction meaning the heart is too stiff to fill properly to meet the body's needs. This study is researching an investigational device (study device) called the Alleviant ALV1 System. Investigational means it has not been approved for commercial use by the Food and Drug Administration. (FDA) This study will test the safety and effectiveness of the Alleviant ALV1 System. The Alleviant ALV1 System is intended to create a shunt (an opening) in the heart to allow for proper blood flow through the heart which may improve your symptoms. No device is left in your heart it is just used to create the shunt. This is a randomized study which means subjects are assigned by chance to either have the study device create this shunt or not have the study device create the shunt. Randomization is 50/50 meaning there is a 50% chance to have the study device create a shunt and a 50% chance the study device will not be used. Using the study device to create the shunt is performed during a right heart catheterization (RHC) so all subjects will undergo the RHC but only 50% will have the shunt. Neither the subjects nor the study doctor will know which group subjects are randomized to but other study staff will know in the event this information is needed. All subjects will stay overnight in the hospital after the procedure. Other study related procedures include echocardiograms - ultrasound test of the heart, electrocardiograms (ECG) - a tracing of the heart's electrical activity, blood work, questionnaires, 6 minute hall walk test, and assessments of heart failure status. Risks include risks related to the study device including blood vessel damage from placing the device in the vein to get to the heart, risks from the right heart catheterization such as bleeding or bruising, abnormal heart beats, and risks related to study related procedures. There may be risks that are not known at this time. Participation in this study is expected to last about 60 months and include approximately 15 in person visits and 3 telephone calls.

This study is enrolling patients with uncontrolled high blood pressure. This study will see if a medication called Zilebesiran can help lower blood pressure. Zilebesiran is an investigational medication meaning it is not approved for commercial use by the Food and Drug Administration (FDA) but it is approved for use in this study. This is a randomized study meaning if you are eligible, you will be assigned by chance, like the flip of a coin to receive Zilebesiran or placebo. Placebo will look like the study medication but will not contain any active ingredients. You and the study team will not know if you are taking Zilebesiran or placebo, both of which are given as an injection under the skin every six months. This study will last between 2.5 and 5 years and include 10-14 visits. Study related procedures include physical exams, medical history including medications, vital signs, blood and urine collection. and electrocardiogram (ECG - a recording of your heart's electrical activity)

This is a post approval study for those being implanted with the WiSE System. Data will be collected from your medical records including medical history, medications, the implant procedure, and device check as well as routine follow up visits, and you will be asked to complete a questionnaire at 3 visits. Participation in this post approval registry will last about 5 years. There is a risk of loss of confidentiality.